| MSD Merck Sharp & Dohme AG - M-M-RVAXPRO, Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension | | 00703 | | 01 | | M-M-RVAXPRO | | Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension | | J07BD52 | | Masern, Kombinationen mit Mumps und Röteln, lebend abgeschwächt | | 13.02.2007 | | |
| | Composition | | Vaccinum attenuatum: virus morbilli vivus (Stamm Edmonston-Enders) min. 1000 U., virus parotitis vivus (Stamm Jeryl Lynn) min. 12500 U., virus rubella vivus (Stamm Wistar RA 27/3) min. 1000 U., gelatina hydrolysata, medium 199, minimal essential medium (MEM), natrii hydrogenoglutamas monohydricus, neomycinum, phenolsulfonphthaleinum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, natrii hydrogenocarbonas, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, sorbitolum 14.5 mg, saccharum, albuminum humanum, natrii hydroxidum, acidum hydrochloridum, pro vitro corresp. natrium 2.45 mg et kalium 0.09 mg.
Solvens: aqua ad iniectabile. | | Packungsbestandteile | | Solvens | | | aqua ad iniectabile 0.5 ml | | | | | | BAG: Principe actif | Concentr. |
|---|
| | 1000 U | | | 12500 U | | | 1000 U |
|
| Lyophilisat et solvant | | | | | | | | Principe actif | Concentr. | informations additionels |
|---|
| | 1000 U | Vaccinum attenuatum | | | 12500 U | | | | 1000 U | |
| | BAG: Principe actif | Concentr. |
|---|
| | 1000 U | | | 12500 U | | | 1000 U |
| | | | Agents auxilliaires | Concentr. |
|---|
| | | | Albumine Humaine | | | Dipotassium Phosphate Anhydre | | | Disodium Phosphate Dihydrate | | | | | | Potassium Dihydrogenophosphate | | | | 199 | | | | | Sodium Dihydrogenophosphate Dihydrate | | | Sodium Hydrogenocarbonate | | | | | | Sodium Hydroxide | | | Neomycine | | | | | | Saccharum | | | Sorbitol | 14.5 mg |
| |
| Solvens | | | aqua ad iniectabile | | | | | | BAG: Principe actif | Concentr. |
|---|
| | 1000 U | | | 12500 U | | | 1000 U |
|
| |
|
